skip to content
Home

Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID)

 

News Subscribe to News

Read more at: Listening to Your Gut: a cross-disciplinary talk at the Cambridge Festival 2025
Speaker panel at the Listening to Your Gut

Listening to Your Gut: a cross-disciplinary talk at the Cambridge Festival 2025

9 April 2025

"What happens in the gut doesn't stay in the gut," said Dr Virginia Pedicord during the talk 'Listening to Your Gut' at the Cambridge Festival 2025.

Read more at: Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

18 March 2025

Maxion Therapeutics , a Cambridge-based biotechnology company co-founded by Dr. John McCafferty , Affiliate Professor at the Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID) and the Department of Medicine, University of Cambridge, has successfully raised $72 million (£58 million) in an...

Read more at: Monoclonal antibodies offer hope for tackling antimicrobial resistance
A Petri dish with a culture of the Superbug Acinetobacter baumannii next to antibiotics Credit: TopMicrobialStock (Getty Images)

Monoclonal antibodies offer hope for tackling antimicrobial resistance

15 January 2025

A team lead by researchers at the University of Cambridge has developed a monoclonal antibody drug, using a technique involving genetically engineered mice, that may help prevent infection from Acinetobacter baumannii , a bacteria associated with hospital-acquired infections, which is particularly common in Asia.

Read more at: Early career researchers win major European funding
plant roots interacting with arbuscular mycorrhizal fungi credit luginbuehl lab

Early career researchers win major European funding

15 January 2025

Nine Cambridge researchers are among the latest recipients of highly competitive and prestigious European Research Council (ERC) Starting Grants. Of 3,500 proposals reviewed by the ERC, only 14% were selected for funding – Cambridge has the highest number of grants of any UK institution. ERC Starting Grants – totalling...

Read more at: AI able to identify drug-resistant typhoid-like infection from microscopy images in matter of hours
salmon ellaniaid

AI able to identify drug-resistant typhoid-like infection from microscopy images in matter of hours

15 January 2025

Artificial intelligence (AI) could be used to identify drug resistant infections, significantly reducing the time taken for a correct diagnosis, Cambridge researchers have shown. The team showed that an algorithm could be trained to identify drug-resistant bacteria correctly from microscopy images alone.

Read more at: Long COVID linked to persistently high levels of inflammatory protein: a potential biomarker and target for treatments
Tired people

Long COVID linked to persistently high levels of inflammatory protein: a potential biomarker and target for treatments

15 January 2025

SARS-CoV-2 triggers the production of the antiviral protein IFN- γ , which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN- y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.

Contact us

Jeffrey Cheah Biomedical Centre
Cambridge Biomedical Campus
University of Cambridge
Puddicombe Way
Cambridge
CB2 0AW

How we use information

University of Cambridge Information Compliance

Medical research participant information guidance

Connect with us

X

Bluesky

LinkedIn

Subscribe to our newsletter

Study at Cambridge

About the University

Research at Cambridge